Literature DB >> 15767055

Iris melanocytoma: clinical features and natural course in 47 cases.

Hakan Demirci1, Arman Mashayekhi, Carol L Shields, Ralph C Eagle, Jerry A Shields.   

Abstract

PURPOSE: To describe the clinical features, natural course, management and histopathologic features of iris melanocytoma.
DESIGN: Single-center retrospective case series. PATIENT POPULATION: Forty-seven consecutive patients (47 eyes) with iris melanocytoma. INTERVENTION PROCEDURE: Data regarding patient and tumor features were analyzed for their impact on the main outcome measures using univariate and multivariate regression models. Kaplan-Meier estimates were used to analyze the main outcomes as a function of time. MAIN OUTCOME MEASURES: Increased intraocular pressure (IOP), tumor seeding, and tumor growth.
RESULTS: Associated findings at initial presentation included iris stromal seeds in 20 patients (43%), and anterior chamber angle seeds in 12 (26%). Intrinsic vascularization and sector cataract were not seen in any eyes. The management at presentation included observation in 39 patients (83%), tumor removal by sector iridectomy/iridocyclectomy in 7 (15%), and enucleation for blind painful eye with secondary increased IOP in 1 (2%). The diagnosis was confirmed by histopathologic examination in 11 patients (23%). The mean follow-up was 58 months. Using Kaplan-Meier estimates, clinical evidence of growth was observed in 23% at 5 years, 48% at 10 years, and 74% at 15 years. New tumor seeds developed in 34% at 5 years, 63% at 10 years, and 75% at 15 years. Increased IOP was observed in 11% at 5 years, 11% at 10 years, and 55% at 15 years.
CONCLUSIONS: Iris melanocytoma represented only 3% of all iris nevi. Related iris stromal and anterior chamber angle seeds were common, and secondary glaucoma occurred in 11% at 5 years. Growth was observed in 23% at 5 years but no malignant transformation was found.

Entities:  

Mesh:

Year:  2005        PMID: 15767055     DOI: 10.1016/j.ajo.2004.10.008

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  14 in total

Review 1.  Don't it make my blue eyes brown: heterochromia and other abnormalities of the iris.

Authors:  I G Rennie
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

2.  Malignant transformation of iris melanocytoma to iris ring melanoma.

Authors:  Mandeep S Sagoo; Prithvi Mruthyunjaya; Ian Cree; Philip J Luthert; John L Hungerford
Journal:  Br J Ophthalmol       Date:  2007-11       Impact factor: 4.638

3.  A case of iris melanocytoma transformed to malignant melanoma.

Authors:  Ryo Inoue; Yoshitsugu Saishin; Chiharu Shima; Hiroshi Yoshikawa; Nobuyuki Ohguro; Yasuo Tano
Journal:  Jpn J Ophthalmol       Date:  2009-05-31       Impact factor: 2.447

4.  Hyphema from Iris Melanocytoma.

Authors:  Neel D Pasricha; Michael I Seider
Journal:  Ocul Oncol Pathol       Date:  2018-10-25

5.  A case of ciliary body melanocytoma presenting as a painful iris mass.

Authors:  Christopher Seungkyu Lee; Do Kyung Kim; Sung Chul Lee
Journal:  Korean J Ophthalmol       Date:  2010-02-05

6.  Iris melanocytoma in child diagnosed by fine needle aspiration biopsy.

Authors:  Samira Awaji; Hind Alkatan; Soliman Al-Kharashi; Ali Al-Rajhi
Journal:  Saudi J Ophthalmol       Date:  2013-08-03

7.  Melanocytoma of the ciliary body misdiagnosed as iridodialysis.

Authors:  Moosang Kim; Seung-Jun Lee
Journal:  Clin Ophthalmol       Date:  2014-05-29

8.  Melanosis oculi.

Authors:  Osama M Mustafa; Yassine J Daoud
Journal:  Am J Ophthalmol Case Rep       Date:  2017-05-19

Review 9.  Review of cystic and solid tumors of the iris.

Authors:  Carol L Shields; Patrick W Shields; Janet Manalac; Chaisiri Jumroendararasame; Jerry A Shields
Journal:  Oman J Ophthalmol       Date:  2013-09

10.  A Case of Iris Melanocytoma Demonstrating Diffuse Melanocytic Proliferation with Uncontrolled Intraocular Pressure.

Authors:  Mami Kusunose; Yuji Sakino; Yoshihiro Noda; Tsutomu Daa; Toshiaki Kubota
Journal:  Case Rep Ophthalmol       Date:  2017-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.